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ackground Limited data exist on the results of a comprehensive TAVI program using different valves
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ethods We report 30-day and 6-month outcomes of high-risk patients consecutively treated in a
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onths was 12.2% in transfemoral, 26.6% in transapical, and 18.2% in transaxillary groups. At multi-
ariable analysis, logistic European System for Cardiac Operative Risk Evaluation, body surface area,
nd history of cerebrovascular disease were signiﬁcantly associated with an increased risk of major
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1111urgical aortic valve replacement (SAVR) is frequently not
n option for patients with symptomatic severe aortic
tenosis considered at high or prohibitive operative risk. For
his patient cohort transcatheter aortic valve implantation
TAVI) represents a promising strategy (1–5). Most studies
ave evaluated the results of TAVI either according to the
pproach used (i.e., transfemoral [1,2], transaxillary [4], or
ransapical [3]) or to the device implanted—Medtronic
oreValve (MCV) (Medtronic, Minneapolis, Minnesota)
2,5,6) or Edwards-SAPIEN valve (ESV) (Edwards Life-
ciences, Irvine, California) (1,7,8). Patients are evaluated
or TAVI in the setting of a multidisciplinary program
ncompassing interventional cardiology and cardiac surgery
eams, with the selection of 1 approach over the other on the
asis of the size and/or disease of the iliofemoral arteries.
imited data exist on the results of a comprehensive TAVI
rogram including transfemoral, transaxillary, and transapi-
al approaches and implantation of MCV or ESV. The
bjective of this single-center retrospective study was to
valuate the acute and midterm follow-up results and the
actors predictive of outcome with the 2 commercially
vailable valves with all 3 delivery approaches selected in a
tepwise fashion.
ethods
atients. From November 2007, all patients with severe
ymptomatic aortic stenosis consecutively referred to our
nstitution (San Raffaele Scientific Institute, Milan, Italy)
or TAVI were evaluated. All patients were evaluated by a
ultidisciplinary team, including 2 interventional cardiolo-
ists, 1 cardiac surgeon, and an anesthesiologist. The
ecision to perform TAVI was made in patients with the
ollowing characteristics: severe symptomatic aortic stenosis
ith an aortic valve area 1 cm2 plus 1 of the follow-
ng: high surgical risk, as defined as a logistic European
ystem for Cardiac Operative Risk Evaluation (logistic-
uroSCORE) 20%, Society of Thoracic Surgeons Pre-
icted Risk of Mortality (STS-PROM) 10%; associated
omorbidities not captured by the 2 scores, such as thoracic
adiotherapy, coronary artery bypass surgery with patent
rafts (a patent graft with right internal mammary artery,
hich crosses from right to left under the sternum and/or a
atent left internal mammary artery, which might be dam-
ged with the second sternotomy required for SAVR),
orcelain aorta, or liver cirrhosis (in Child-Pugh Class B
nd C); or marked patient frailty that the cardiac surgeon
onsidered to increase the risk for standard SAVR. The
reatment selection algorithm is shown in Figure 1 (9). The
ransfemoral approach was considered the treatment of
hoice; if the peripheral vascular anatomy was not suitable,
he transaxillary or the transapical access was evaluated.
ulmonary hypertension was defined as a pulmonary systolic
ressure 60 mm Hg as estimated by Doppler echocardi- egraphy or measured by cardiac catheterization. Frailty was
efined according to the criteria of Fried et al. (10). Chronic
idney disease was defined as an estimated glomerular
ltration rate 60 ml/min/1.73 m2 (11). Acute renal failure
as defined as a decrease 25% in estimated glomerular
ltration rate at 48 h after the procedure (Risk, Injury,
ailure, Loss and End-stage Kidney criteria) (12) or the
eed of renal replacement therapy (RRT) during index
ospital stay. All patients provided written informed con-
ent for the procedures.
rocedures and devices. Procedures were performed in a
atheterization laboratory, with the exception of transapical
rocedures, which were performed in an operating room.
epending on the preference of the physician, clinical
onditions, and evaluation of the patient by the anesthesi-
logist, the procedure was performed under either general
nesthesia or local anesthesia with conscious sedation. The
ransapical procedures were all carried out under general
nesthesia. The devices used in
his study were the Edwards-
APIEN THV (Edwards Life-
ciences) and the Medtronic
oreValve ReValving Technol-
gy (Medtronic). We began
ith the ESV in November
007 and then later added the
CV to our practice in July
008. The transfemoral and the
ransaxillary routes were used for
oth valves, whereas the trans-
pical was used only for the
SV. After TAVI, dual anti-
latelet therapy was recom-
ended with aspirin, 100 mg
aily indefinitely and clopi-
ogrel, 75 mg daily or ticlopi-
ine, 250 mg twice daily (for 3 months for the ESV valve
nd 6 months for the MCV).
RANSFEMORAL DELIVERY TECHNIQUE. Arterial access
nd closure of the access sites were performed percutane-
usly with a “crossover protection technique” previously
escribed by our group (13). The valve was crossed and
mplanted as previously described (1). After the valve was
eployed, the delivery system was removed; the large intro-
ucer sheath was retrieved up to the junction of the distal
orta and the right common iliac artery while an appropri-
tely sized Fox PTA balloon (Abbott Vascular, Santa Clara,
alifornia) was passed over the guidewire into the right
ommon iliac artery. Contrast was injected to identify any
ight common or external iliac rupture; if none was present,
he PTA balloon was advanced into the external iliac artery,
nd the sheath was further removed (13). Once sutures were
ecured, the PTA balloon was deflated. If there was any
Abbreviations
and Acronyms
ESV  Edwards-SAPIEN
valve
EuroSCORE  European
System for Cardiac Operative
Risk Evaluation
MACCE  major adverse
cardiac and cerebrovascular
event(s)
MCV  Medtronic-CoreValve
RRT  renal replacement
therapy
SAVR  surgical aortic valve
replacement
TAVI  transcatheter aortic
valve implantationvidence of extravasation, the balloon was left inflated for 10
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1112in at 2 atm. A check angiography was performed, and if
o leak was evident the balloon was removed and arterial
heaths appropriately removed after protamine was given in
1:1 fashion with heparin (10 mg of protamine/1,000 UI of
eparin). Hemostasis was achieved on the contralateral side
hrough manual compression. If rupture was evidenced,
urgical or percutaneous repair was performed; in this case,
or more covered endoprostheses, such as the CP STENT
NuMed, Inc., Hopkinton, New York), the Gore Viabahn
W.L. Gore and Associates, Inc., Flagstaff, Arizona), and
he Gore Hemobahn (W.L. Gore and Associates, Inc.)
ere used.
RANSAPICAL APPROACH. All patients received general an-
sthesia and an anterolateral mini-thoracotomy was per-
ormed with opening of the anterolateral segment of the
ericardium near the apex, and the valve was then implanted
Figure 1. Flow Chart for TAVI Patients Selection
Recently, a “transaortic” approach of transcatheter aortic valve implantation (T
posed as an alternative minimally invasive surgical access route (9). AS  aort
ing; EuroSCORE  European System for Cardiac Operative Risk Evaluation; LIM
Society of Thoracic Surgeons Predicted Risk of Mortality.s previously reported (14). iRANSAXILLARY APPROACH. This procedure required sur-
ical isolation of the left axillary artery. Once the artery was
solated, a purse string suture was placed to allow subse-
uent closure at the end of the procedure. The artery was
unctured at the distal end of the purse string, and a 6-F
heath was placed into the artery. The standard 0.035-inch
uidewire was then exchanged for a pre-shaped 0.035-inch
mplatz Super or Extra Stiff guidewire, and a 10-F sheath
as positioned in the axillary artery. The valve was crossed
ith the same procedure as previously described for the
ransfemoral approach (1). The axillary access site was
urgically repaired.
eﬁnitions. Procedural, 30-day, and 6-month outcome
ere evaluated. “Device success” was defined as implanta-
ion of the device with final mean transaortic gradient 20
m Hg without aortic regurgitation grade 3 (effective
ith the Medtronic-CoreValve (Medtronic, Minneapolis, Minnesota) was pro-
osis; AVR  aortic valve replacement; CABG  coronary artery bypass graft-
ft internal mammary artery; MLD  minimal lumen diameter; STS-PROM AVI) w
ic sten
A  lemplantation) and no valve embolization or need to implant
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1113second valve. “Procedural success” was defined as an
ffective valve implantation without intraprocedural mortal-
ty or conversion to open heart surgery. “Vascular compli-
ations” were divided into major and minor complications
ccording to the definitions previously provided (15). “Ma-
or vascular complications” were defined as vessel rupture
nd/or limb-threatening ischemia or bleeding requiring
dditional percutaneous treatment with stent implanta-
ion and/or nonplanned vascular surgery; aortic dissection
as also included. Timing of events was: procedural
until the patient left the catheterization laboratory
nd/or occurring before extubation), 30-day, and 6-month
linical follow-up. Outcome measures included major ad-
erse cardiac and cerebrovascular events (MACCEs) at 30
ays and 6 months and major adverse valve-related events at
0 days. The MACCEs included cardiovascular death
death related to cardiac causes and major vascular compli-
ations such as retroperitoneal hematoma and TAVI-
Table 1. Baseline Characteristics of Study Population
Transfemoral
Patients, n 107
Edwards-SAPIEN THV 61 (57)
Medtronic CoreValve 46 (43)
Age, yrs 79.7 7
Male 56 (52)
BMI, kg/m2 33.4 5.7
BSA, m2 1.73 0.24
Diabetes 31 (29)
Chronic kidney disease 39 (36.4)
Porcelain aorta 17 (15.9)
COPD 46 (43)
Pulmonary hypertension 44 (41)
Previous myocardial infarction 29 (27)
Previous PCI 24 (22.4)
Previous CABG 23 (21.5)
Cerebrovascular disease 20 (18.7)
Peripheral vascular disease 26 (24.3)
History of angina 22 (20.5)
History of syncope 20 (18.7)
NYHA functional class III to IV 75 (70)
Logistic EuroSCORE 26.6 16
STS-PROM score 7 4.9
Mean aortic gradient, mm Hg* 54 17.2
Aortic annulus diameter, mm* 23.11 2.0
Aortic regurgitation grade 3–4* 16 (15)
LVEF* 50.8 12.9
LVEF 35% 17 (15.9)
Iliofemoral artery MLD, mm† 7.82 1.06
Values are expressed as n (%) or mean SD. *Echocardiographic mea
BMI  body mass index; BSA  body surface area; COPD  chron
EuroSCORE  European System for Cardiac Operative Risk Evaluation
NYHA  New York Heart Association; PCI  percutaneous coronaryMortality.elated aortic dissection), myocardial infarction, stroke,
ortic valve re-intervention, or urgent cardiac or vascular
urgery. Major adverse valve-related events included valve-
elated mortality, valve-related morbidity, and need for new
ermanent pacemaker or defibrillator within 14 days after
he procedure (7).
tatistical analysis. Continuous variables were reported as
ean  SD or median (25th to 75th interquartile range)
nd compared with Student t test or Mann-Whitney or
ilcoxon rank-sum test, depending on variable distribu-
ion. Categorical variables were compared with chi-square
est with Yates correction for continuity or the Fisher exact
est as appropriate (16). The 1-way analysis of variance was
sed to test the hypothesis that several echocardiographic
easurements are equal. Levene’s test was used to test homo-
eneity of variance, and the Bonferroni test was performed
s post hoc range test (17). Procedural and outcome results
f transfemoral, transapical, and transaxillary approaches are
Transapical Transaxillary p Value
15 15
15 (100) 3 (20) 0.0001
— 12 (80) 0.0001
78.8 6.5 78.7 5 0.794
5 (33) 12 (80) 0.034
24.5 4.4 25.6 3.4 0.749
1.64 0.16 1.72 0.22 0.266
4 (26.7) 5 (33) 0.917
5 (33) 7 (46.7) 0.706
14 (93.3) 7 (46.7) 0.0001
6 (40) 11 (73) 0.077
5 (33) 4 (26.7) 0.506
5 (33) 6 (40) 0.549
6 (40) 3 (20) 0.305
8 (53) 4 (26.7) 0.030
8 (53) 3 (20) 0.011
10 (67.7) 12 (80) 0.0001
6 (40) 3 (20) 0.233
3 (20) 1 (6.7) 0.549
11 (73.3) 9 (60) 0.685
32.2 23 28.6 14 0.477
8.3 4.2 6.9 2.8 0.602
44.7 18 47.7 14.9 0.074
22.30 1.23 24.00 0.61 0.014
2 (13) 1 (6.7) 0.684
50 12.5 52.8 11 0.814
2 (13) 1 (6.7) 0.632
6.27 1.00 6.23 1.03 0.0001
nts; †angiographic multislice computed tomography measurements.
uctive pulmonary disease; CABG  coronary artery bypass grafting;
 left ventricular ejection fraction; MLD  minimal lumen diameter;
ntion; STS-PROM  Society of Thoracic Surgeons Predicted Risk ofsureme
ic obstr
; LVEF
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1114rovided but not compared, due to the differences in
aseline and procedural characteristics. Multivariable binary
ogistic regression analysis (with a purposeful selection
lgorithm) was performed to determine the independent
redictors of death and MACCEs at 6-month follow-up.
ariables associated in the univariate binary logistic regres-
ion analysis with death and MACCEs (p  0.1) and those
udged to be of clinical importance from previous published
ata were eligible for inclusion into the multivariable
odel-building process. To avoid over-fitting the number
f independent variables entered into the final multivariable
odel was limited to a maximum of 1 for every 10 events.
ajor vascular events were not included in the multivariate
odel of predictors of MACCEs, because they are already
art of the MACCEs definition. Model discrimination was
easured by the C-statistic and the Hosmer-Lemeshow
oodness-of-fit test (18). All statistical analysis was per-
ormed with SPSS version 16.0 (SPSS, Inc., Chicago,
llinois), with significance set at the 2-tailed 0.05 level.
esults
aseline characteristics. Between November 2007 and Feb-
uary 2010, 137 patients with symptomatic, severe aortic
Table 2. Transfemoral Approach
Edward
Patients, n
Age, yrs 80
Male 28
BMI, kg/m2 40
BSA, m2 1.71
Diabetes 17
Chronic kidney disease 24
Porcelain aorta 12
COPD 25
Pulmonary hypertension 29
Cerebrovascular disease 12
Previous myocardial infarction 16
Previous PCI 13
Previous CABG 12
NYHA functional class III to IV 44
Logistic EuroSCORE 27.1
STS-PROM score 7.2
TAVI in degenerated bioprosthesis 4
Mean aortic gradient, mm Hg* 55.5
Aortic annulus diameter, mm* 22.6
Aortic regurgitation grade 3–4* 6
LVEF* 51
LVEF 35% 10
Iliofemoral artery MLD, mm† 7.88
Values are expressed as n (%) or mean  SD. *Echocar
tomography measurements.TAVI transcatheter aortic valve implantation; other abbreviatitenosis underwent TAVI in our center and were included
n this analysis. Baseline clinical and echocardiographic
haracteristics of the study population are shown in Table 1.
he approach for TAVI was transfemoral in 107 patients
78%), transaxillary in 15 (11%), and transapical in 15
11%). The ESV was implanted in 79 patients (57.7%), 61
77%) via the transfemoral approach, 15 (19%) via the
ransapical approach, and 3 (4%) via the transaxillary ap-
roach. Four (6.6%) of these patients had an ESV im-
lanted for a degenerated bioprosthetic aortic valve (valve-
n-valve). The MCV device was implanted in 58 patients
42.3%); 46 patients (79.3%) were treated via the transfemo-
al approach, and 12 (20.7%) were treated via the transax-
llary approach. Assessment of the transfemoral approach
howed that the only difference between patients treated
ith ESV and MCV was related to the aortic annulus
iameter, which was significantly smaller in the ESV group
p  0.001) (Table 2).
rocedural and 30-day outcomes. TRANSFEMORAL APPROACH.
rocedural and 30-day clinical outcomes are reported in
able 3. The transfemoral approach was performed under
eneral anesthesia in 30 of 107 patients (28%), 24 of 61
atients with ESV (39.3%), and in 6 of 46 patients with
EN Medtronic CoreValve p Value
46
79 7.5 0.375
28 (61) 0.090
25 4 0.214
1.75 0.1 0.416
14 (30) 0.831
15 (32.6) 0.545
5 (10.9) 0.289
21 (45.7) 0.629
15 (32.6) 0.165
8 (17.4) 0.807
13 (28) 0.829
11 (24) 0.817
11 (24) 0.640
31 (67) 0.374
26.0 15.5 0.713
6.8 5.0 0.710
1 (2.2) 0.102
52 15 0.336
23.7 1.6 0.001
10 (21.7) 0.105
50.5 14 0.861
7 (15.2) 1.000
7.72 1.07 0.500
hic measurements; †angiographic multislice computeds-SAPI
61
 6
(46)
 7
 0.3
(28)
(39)
(19.7)
(41)
(47.5)
(19.7)
(26)
(21)
(19.7)
(72)
 16.4
 4.9
(6.6)
 18
 1.4
(9.8)
 12
(16.4)
 1.06
diograpons as in Table 1.
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1115VC (13%), p  0.003. Elective surgical cut down of the
ommon femoral artery was used in 5.6% of cases (4.3%
SV and 6.6% MCV). Procedural success was observed in
3.5% of patients and was significantly higher in the ESV
roup compared with the MCV group (98.4% vs. 89%,
espectively; p  0.040). There were no intra-procedural
eaths. A total of 22 major vascular complications (20.6%)
ccurred (Table 4).
SV outcome. Procedural failure occurred in 1 of 61 patients
1.6%): the patient had an ascending aortic dissection soon
fter implantation of ESV (in a bicuspid valve), and the
rocedure was immediately converted to open surgical
epair. No valve embolization occurred with the ESV. The
ajor vascular complication rate was 21.3% (Table 4). Two
atients (3.3%) had neurological events: 1 patient had a
ransient ischemic attack, and 1 experienced a stroke on the
ame day of the procedure. No death occurred at 30-day
linical follow-up.
CV outcomes. Procedural failure occurred in 5 of 46
Table 3. Clinical Outcomes After Transfemoral TAVI A
A
Patients, n
Hospital stay, days*
Procedural success
Procedural success without major vascular complication
Valve embolization
“Valve after valve”
Aortic regurgitation grade 3–4
Vascular complications
Major vascular complications
Need for surgical vascular repair
Need for permanent pacemaker
Neurological events/stroke 3
MOF/sepsis
Acute renal failure requiring RRT
30-day clinical outcomes
Death
Cardiac death
MACCE
MAVREs
LVEF
6-month cumulative clinical outcomes
Eligible patients 9
Death
Cardiac death
Sudden death
MACCE
Mean aortic gradient, mm Hg 1
LVEF 5
Values are expressed as n (%) or mean SD. *Procedure to discharge
MACCE  major adverse cardiac and cerebrovascular event(s); MA
MVCmajor vascular complication; RRT renal replacement therapyatients (11%): 5 patients needed a second valve implan- iation during the same MCV implantation. In 3 of them
second valve was successfully implanted, after emboli-
ation of the first MCV in the ascending aorta and/or
ortic arch after implantation. In 2 patients (4.3%) severe
esidual aortic regurgitation after the first MCV required
mplantation of a second valve (valve after valve): in 1
atient an MCV 29 mm was immediately implanted in an
CV 26 mm; in a second patient an ESV 26 mm was
mplanted to decrease the severity of residual aortic
egurgitation 6 days after implantation of an MCV 29
m (for primary aortic regurgitation). One patient
2.2%) had a transient ischemic attack. No strokes
ccurred more than 24 h after the procedure. The overall
ncidence of permanent pacemaker implantation was
7.8% and was significantly higher with the MCV than
he ESV (26.1% vs. 11.5%, respectively; p  0.050). One
eath (2.2%) occurred within 48 h of the procedure from
emorrhagic shock due to retroperitoneal bleeding in a
atient with vascular rupture treated with covered stent
ch
ents Edwards-SAPIEN Medtronic CoreValve p Value
61 46
1.4 8.4 0.8 11 3 0.328
93.5) 60 (98.4) 41 (89) 0.041
87.9) 56 (91.8) 38 (82.6) 0.150
2.8) 0 3 (6.5) 0.032
4.7) 0 5 (10.8) 0.013
6.5) 4 (6.6) 3 (6.5) 1.000
29) 18 (29.5) 13 (28.3) 0.888
20.6) 13 (21.3) 9 (19.6) 0.825
9.3) 5 (8.2) 5 (10.8) 0.638
17.8) 7 (11.5) 12 (26.1) 0.073
(0.9) 2 (3.3)/1 (1.6) 1 (2.2)/0 0.732
8.4) 5 (8.2) 4 (8.7) 0.927
4.7) 2 (3.3) 3 (6.5) 0.650
0.9) 0 1 (2.2) 0.430
0 0 —
13.1) 7 (11.5) 7 (15.2) 0.578
29.9) 14 (23) 18 (39) 0.089
11.5 53.17 10.8 51.78 12.4 0.555
92) 60/61 (98) 38/46 (83)
12.2) 5 (8.3) 7 (18.4) 0.205
2.0) 0 2 (5.3) 0.148
2.0) 0 2 (5.3) 0.141
21.4) 10 (16.7) 11 (28.9) 0.149
9.4 11.32 10.6 9.20 6.8 0.294
9.1 53.21 9.3 53.23 9.0 0.994
r hospital.
major adverse valve-related event(s); MOF  multiple organ failure;
transient ischemic attack; other abbreviations as in Tables 1 and 2.pproa
ll Pati
107
9.5
100 (
94 (
3 (
5 (
7 (
31 (
22 (
10 (
19 (
(2.8)/1
9 (
5 (
1 (
0
14 (
32 (
52.6
8/107 (
12 (
2 (
2 (
21 (
0.52
3.22
from ou
VRE mplantation (Patient #14 in Table 4).
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1116RANSAPICAL APPROACH. Procedural and clinical out-
omes are reported in Table 5. Procedural failure occurred
n 2 of 15 patients (13.4%): 1 patient (6.7%) had left
entricular rupture successfully treated with placement of a
atch during extracorporeal circulation oxygenation; a sec-
nd patient had residual massive aortic regurgitation after
he first ESV 23 mm implantation that required a second
SV 23 mm (valve after valve) implantation during extra-
orporeal circulation oxygenation. No intra-procedural
eath occurred. In 1 patient ESV implantation caused right
oronary artery ostium occlusion without clinical conse-
uence (nondominant vessel). One patient had a transient
schemic attack within 24 h after the procedure. The 30-day
ardiovascular death rate was 13.4% (n  2): 1 patient died
2 h after a transapical procedure from a cardiac arrest
ventricular fibrillation) with unsuccessful cardiopulmonary
esuscitation; a second patient died after 5 days for untreat-
ble ventricular fibrillation storm without any evident un-
erlying cause.
RANSAXILLARY APPROACH. Procedural and clinical out-
omes are reported in Table 5. Procedural failure occurred
n 1 of 15 patients (6.6%): the patient had residual severe
ortic regurgitation after the first MCV 26 mm that
equired early implantation of a second MCV 29 mm (valve
fter valve). Moreover, other complications (not defined as
Table 4. Patients With Major Vascular Complications
Patient # Number in Series Approach and Valve Site
1 4 TF ESV CFA
2 10 TF ESV CIA
3 11 TF ESV EIA
4 13 TF ESV EIA
5 28 TF ESV CFA
6 50 TF MCV CFA
7 51 TF ESV Ascending aorta
8 60 TF MCV CFA
9 70 TF MCV CFA
10 74 TF ESV CFA
11 75 TF ESV EIA
12 83 TF ESV CFA
13 95 TF MCV CFA
14 96 TF MCV EIA
15 107 TF ESV CFA
16 112 TF MCV CFA
17 116 TF ESV EIA
18 120 TF MCV EIA
19 121 TF ESV EIA
20 126 TF MCV CFA
21 135 TF MCV CFA
22 136 TF ESV CFA
CFA  common femoral artery; CIA  common iliac artery; EIA  external iliac artery; ESV 
TF transfemoral approach.rocedure failure) occurred in 2 patients: 1 had residual bortic dissection after MCV implantation treated conserva-
ively (the patient had a transitory ischemic attack 48 h
ater); a second patient had dissection of the subclavian
rtery and consequent occlusion of the left internal mam-
ary artery graft to the left anterior descending coronary
rtery soon after implantation of an ESV valve. This patient
emained clinically stable and an unsuccessful attempt to
e-open the graft was made. No death occurred in the
ransaxillary group. Echocardiographic results are summa-
ized in Figure 2. Post-procedural mild para-valvular regur-
itation was a recurrent finding (trivial or mild: 72%,
oderate: 4%, severe: 1.5%) (Fig. 2B). No significant
ifferences in terms of post-procedural moderate-to-severe
ara-valvular regurgitation was found after comparison of
SV and MCV devices (5.1% vs. 6.9%).
-month clinical follow-up. TRANSFEMORAL APPROACH.
t 6 months, 98 of 107 patients (92%) were eligible for
ollow-up and no patient was lost to follow-up. The results
re reported in Table 3. The cumulative all-cause mortality
ate was 12.2% (12 patients). Two deaths were adjudicated
s cardiac (2%), both involving patients treated with MCV
p  0.073), and both were sudden deaths occurring at 63
nd 121 days. Six patients died 30 days after the procedure
hile still in-hospital: 3 died of hemorrhagic shock (2
etroperitoneal hematoma, and 1 after tracheostomy), 2
Complication Treatment Clinical Outcome
ection Surgery Resolved
ture PTA with stent implantation Death (at 55 days)
ture PTA with stent implantation Resolved
ture PTA with stent implantation Resolved
mbosis and embolization Surgery Resolved
doaneurysm Surgery Resolved
ection Surgery Death (at 35 days)
doaneurysm Surgery Resolved
doaneurysm Surgery Resolved
tar device failure Surgery Resolved
ture PTA with stent implantation Resolved
ection PTA with stent implantation Resolved
ture PTA with stent implantation Death (at 2 days)
ection PTA with stent implantation Death (at 60 days)
tar device failure Surgery Resolved
tar device failure Surgery Resolved
ection PTA with stent implantation Resolved
ection PTA with stent implantation Resolved
ture PTA with stent implantation Resolved
ture PTA with stent implantation Resolved
doaneurysm Surgery Death (at 50 days)
tar device failure PTA with stent implantation Resolved
ds-SAPIEN valve; MCV  Medtronic-CoreValve; PTA  percutaneous transluminal angioplasty;Diss
Rup
Rup
Rup
Thro
Pseu
Diss
Pseu
Pseu
Pros
Rup
Diss
Rup
Diss
Pros
Pros
Diss
Diss
Rup
Rup
Pseu
Pros
Edwarecause of multi-organ failure from sepsis, and 1 after
a
o
O
l
T
m
f
1
6
t
r
d
m
w
I
(
t
a
w
t
c
w
f
P
m
T
m
a
m
o
f
f
D
T
r
p
t
a
p
t
i
p
n
M
o
c
r
w
o
O
r
3
t
m
r
b
W
w
m
a
l
e
m
t
3
W
p
d
t
t
p
o
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 1 , 2 0 1 0 Godino et al.
N O V E M B E R 2 0 1 0 : 1 1 1 0 – 2 1 TAVI With Edwards-SAPIEN and CoreValve Devices
1117scending aortic dissection. A further 3 patients died out-
f-hospital from multi-organ failure and recurrent infection.
ne patient had a stroke at 136 days and died some days
ater.
RANSAPICAL AND TRANSAXILLARY APPROACHES. Six-
onth clinical outcomes are reported in Table 5. Clinical
ollow-up was performed in all transapical patients and in
1 of 15 (73%) transaxillary patients considered eligible for
-month follow-up. In the transapical group, the cumula-
ive death rate was 26.6% (n  4), and all were cardiac-
elated (2 within 30 days as previously described). Of the 2
eaths that occurred after 30 days, 1 was related to a
yocardial infarction (at 142 days), and 1 involved a patient
ith a post-procedural ventricular septal defect (at 84 days).
n the transaxillary group, the overall death rate was 18.2%
2 deaths), and 1 was cardiac due to chronic heart failure. In
his series of patients, 8 of 30 (26%) patients with porcelain
orta had a logistic-EuroSCORE 15. Of these, 5 patients
ere treated by the transfemoral approach, and 2 were
reated by the transapical approach. A major vascular
Table 5. Clinical Outcome After Transapical and Transaxillary
TAVI Approach
Transapical Transaxillary
Patients, n 15 15
Hospital stay, days 15.8 4.8 8.7 1
Procedural success 13 14
Valve embolization 0 0
“Valve after valve” 1 1
Aortic regurgitation grade 3/4 2 1
Vascular complications — 2
Major vascular complications — 1
Need for permanent pacemaker 3 1
Neurological events/stroke 1/0 1/0
MOF/sepsis 3 0
Acute renal failure requiring RRT 4 2
30-day clinical outcome
Death 2 0
Cardiac death 2 0
MACCEs 3 1
MAVREs 7 1
LVEF 49.67 10.4 52.73 10.1
6-month cumulative clinical outcome
Eligible patients 15/15 (100) 11/15 (73)
Death 4 2
Cardiac death 4 1
Sudden death 2 0
MACCEs 6 2
Mean aortic gradient, mm Hg 18.91 8.1 8.91 2.8
LVEF 56.22 4.12 60.23 3.45
Values are expressed as n, mean SD, or n (%).
Abbreviations as in Table 3.omplication occurred in 2 of them (2 iliac ruptures treated bith stent implantation). Only 1 death occurred at 64-day
ollow-up and was cardiac-related (congestive heart failure).
REDICTORS OF 6-MONTH ADVERSE EVENTS. Results of
ultivariable logistic regression analysis are reported in
able 6 (univariate analysis in Online Table 7). In the
ultivariable analysis, logistic-EuroSCORE, body surface area
nd a prior history of cerebrovascular disease emerged as the
ost significant independent predictors for MACCEs. More-
ver, significant predictors of death during the 6-month
ollow-up period were low LVEF and post-TAVI acute renal
ailure requiring RRT.
iscussion
o the best of our knowledge, this is the first study
eporting TAVI outcomes from a single center offering all
ossible combinations for transcatheter treatment of symp-
omatic aortic stenosis, using both devices currently avail-
ble on the market and 3 types of access. The overall
rocedural success rate of 92.7% is encouraging, suggesting
hat—with careful screening and appropriate technique—
mmediate procedural success can be achieved in most
atients in whom the procedure is attempted. In this series
o death occurred during the procedure.
ortality rate. The overall 30-day death rate with the ESV
f 2.5% (2 deaths, both after the transapical approach) is low
ompared with published death rates and is 1 of the lowest
eported at 30-day for the ESV. The 30-day rate of death
as 8.5% in the combined transapical and transfemoral arms
f the SOURCE (SAPIEN Aortic Bioprosthesis European
utcome) Registry (the largest consecutive patient TAVI
egistry reported to date) (8). Webb et al. (7) reported a
0-day mortality of 11.3%, lower in the transfemoral group
han transapical (8.0% vs. 18.2%), whereas in a more recent
ulticenter report on ESV from Canada the overall death
ate at 30 days was 10.4% with no significant difference
etween the transfemoral and the transapical approach (19).
ith regard to the MCV our overall 30-day mortality rate
as 1.7% (1 death), compared with the lowest reported
ortality rate of 6.7% for the transfemoral approach (20)
nd 9.4% for transaxillary approach (21) (Figs. 3 and 4). The
ow rate of procedural and 6-month mortality cannot be
xplained by the baseline characteristics of our patients. The
ean logistic-EuroSCORE of our patients treated with
ransfemoral and transapical approach was 26.6% and
2.2%, respectively, and was similar to that reported by
ebb et al. (7) (25% and 35%, respectively). However, it is
ossible that the opportunity to select between 2 different
evices and 3 different delivery approaches and the use of
he crossover balloon technique has allowed us to implant
he best possible valve by the best delivery method for each
atient with a safer approach. Furthermore, the increased
verall mortality rate at 6-month follow-up (14.5%) might
e explained by the large burden of disease, due to multiple
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1118omorbid factors associated with this complex patient pop-
lation, resulting in poor long-term prognosis.
omparison of transfemoral ESV and MCV implantation.
resently, there are few data reporting a direct comparison
etween the 2 types of device within a single center (22–24).
n our experience, patients selected for the transfemoral
pproach with both valves were no different in terms of
aseline clinical characteristics except for differences in the
ortic annulus diameter, which was predictably smaller in
he ESV patients. The MCV implantation was character-
zed by a significantly lower rate of procedural success (p 
.040), a higher rate of valve embolization (p  0.041), and
eed for a second valve (“valve after valve,” p  0.013).
oreover, the frequency of permanent pacemaker implan-
ation is greater after an MCV procedure compared with
SV (26.1% vs. 11.5%, p 0.073). In the study reported by
chetche et al. (22), the rate of permanent pacemaker was
Figure 2. Echocardiographic Results
(A) Mean and peak aortic gradient. (B) Aortic regurgitation (AR) in all transcath
Table 6. Multivariate Analysis of Candidate Predictors for 6-Month Adverse
Endpoint Predictor Variable* Predictor Variable Presen
MACCE Logistic-EuroSCORE, BSA (m2),
cerebrovascular disease, LVEF
(35.3 20 vs. 25.4
(1.60 0.34 vs. 1.75
(41.4% vs. 18.1%)
(46.5 15.4 vs. 52.8
Deaths LVEF ARF requiring RRT STS score (41.2 16.3 vs. 53.0
(27.8% vs. 3.8%)
(10.7 7.4 vs. 6.6 3
*Reported all significant predictor variables derived frommultivariate binary logistic regression anaARF acute renal failure; CI confidence interval; H-L Hosmer-Lemeshow Goodness-of-Fit; other abb8.6% and 4.2% in the MVC and ESV groups, respectively
p 0.002). Similarly, Bleiziffer et al. (23) reported a rate of
ermanent pacemaker of 27% and 6%, respectively (p 
.008). As previously reported (22) there was no statistically
ignificant difference in vascular complication between ESV
nd MCV patients.
ajor vascular complications. Major vascular complications,
rimarily iliofemoral dissection or perforation, occurred in
2 patients (20.6%) with the transfemoral approach (18%,
onsidering all patients with a transarterial approach). Our
ate of vascular complications was not much higher than the
ange of 4% to 16.7% in previously published reports, which
aried on the basis of the specific definitions of major
ascular complications (Online Table 8) and the kind of
rosthesis used in each study. In previous studies with ESV,
ebb et al. (7) reported a vascular injury rate of 8%,
hereas Ducrocq et al. (25) quoted a rate of 16.7%.
ortic valve implantation (TAVI) patients alive at 6-month follow-up.
omes
bsent p Value Odds Ratio (95% CI) c-Statistic H-L Test
0.010
0.011
0.015
0.149
1.038 (1.009–1.067)
0.023 (0.001–0.428)
0.277 (0.099–0.778)
0.971 (0.933–1.011)
0.792 0.490
0.004
0.015
0.095
0.941 (0.902–0.980)
0.126 (0.024–0.670)
1.109 (0.982–1.253)
0.811 0.810
d also the first of those nonsignificant with the higher p value.Outc
t vs. A
14)
0.16)
11)
10)
.6)
lysis anreviations as in Table 3.
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1119imilarly, Bleiziffer et al. (26) in a single-center registry of
53 transfemoral TAVI procedures (most of which were
erformed with MCV) reported a femoral vessel complica-
ion rate of 16%. In addition, the availability of the option
o treat our patients with both valves and the use of the
crossover protection technique” allowed us to use the
ransfemoral approach without the need for elective surgical
Figure 3. Procedural Failure and 30-Day Mortality After TAVI
Transcatheter aortic valve implantation (TAVI) with the Edwards-SAPIEN valve (
procedural failure varied in each study on the basis of the speciﬁc deﬁnitions
(Placement of Aortic TraNscathER Valve Europe) Trial Investigators (Oral presen
European Outcome.
Figure 4. Procedural Failure and 30-Day Mortality After TAVI
Transcatheter aortic valve implantation (TAVI) with the Edwards-SAPIEN valve (
via the transaxillary approach (B).losure in 94.4%. However, it is important to highlight that,
espite a high occurrence of major vascular complications,
he transarterial approach 30-day mortality was only
.2%. The recent introduction of the SAPIEN XT valve
ith 18- and 19-F introducers might further help to
inimize the risk of vascular complications in centers using
nly this valve (27).
d the Medtronic CoreValve (B) via the transfemoral approach. Deﬁnition of
cedural success (Online Table 8). *Schalinger V; on behalf of the PARTNER EU
at Euro PCR 2009, Barcelona, Spain). SOURCE  SAPIEN Aortic Bioprosthesis
transapical approach, and Edwards-SAPIEN valve and Medtronic CoreValveA) an
of pro
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1120redictors of clinical outcome. We analyzed various clinical,
uantitative, morphological, and procedural events poten-
ially affecting 6-month outcome. It is not surprising that
ow ejection fraction and acute renal failure requiring RRT
ere significant independent predictors of death, because
oth are important indexes of patient vulnerability. In a
ecently published report by Bagur et al. (28) acute kidney
njury after TAVI was found to be associated with a 4-fold
ncrease in the risk of post-operative mortality. Addition-
lly, the incidence of MACCEs was predicted by lower
ody surface area and a prior history of cerebrovascular
isease. That logistic-EuroSCORE was an independent
redictor of MACCEs but not mortality might be because
his score was constructed as a pre-assessment tool for
urgical procedures and might be inaccurate at predicting
utcome after percutaneous procedures. Recently, Piazza et
l. (29) found a moderate correlation between logistic-
uroSCORE and Society of Thoracic Surgeons Predicted
isk of Mortality score and reported that both risk scores
ad suboptimal discriminatory power and calibration. Sim-
larly, Thomas et al. (8) demonstrated low discriminatory
ower of the logistic-EuroSCORE for TAVI patients
nrolled in the SOURCE Registry. A general shortcoming
f all surgical risk scores is the lack of several measurable and
mmeasurable risk factors that can influence patient selec-
ion and outcome. Additionally, in both scores a number of
ariables, such as porcelain aorta, chest radiation, liver
irrhosis, marked patient frailty, and others, are omitted.
tudy limitations. This study reflects a single-center expe-
ience, and although the sample size is acceptable, the
umber of patients treated with each combination of valve
ype and approach was relatively limited. Moreover, the
umber of ESV is almost double the number of MCV. In
ur center the MCV became available later than the ESV,
nd therefore some vascular complications that occurred
ith the early ESV experience could have been avoided with
he MCV and might be a reflection of our learning curve
ith the procedure. The small number of patients might
ave had implications on the validity of our analysis of
redictors due to a lack of sufficient power, particularly with
espect to the detection of confounding factors. Finally, this
nalysis focused on outcome events up to 180 days from the
rocedure and was thus not aimed at detecting complica-
ions associated with longer-term follow-up.
onclusions
ranscatheter aortic valve implantation is a very promising
trategy that has great potential in allowing the treatment of
atients with severe aortic stenosis, who are at very high
urgical risk and were previously deemed unfit for SAVR. In
his study the availability of 2 different devices, delivered via
different approaches, has made this intervention increas-
ngly feasible for a wider range of high-risk patients.lthough our preliminary results are encouraging, only
andomized controlled trials and larger registries with
onger follow-up will help to delineate the safety and
urability of this strategy. At present, rigorous patient
election, individualized decision-making, and full cooper-
tion of the multidisciplinary team is paramount to ensure
hat each individual receives the best possible treatment
odality with the maximal safety and efficacy.
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